3Stratton IM,Adler AL,Neil HA,et al.Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35):prospective observational study[J].BMJ,2000,321(7258):405.
3Mason RM and Wahab NA. Extracellular Matrix Metabolism in Diabetic Nephropathy[J]. J Am Soc Nephrol, 2003, 14: 1358.
4Eddy A A. Plasminogen activator inhibitor-1 and the kidney [J]. Am J Physiol Renal Physiol, Aug, 2002, 283.. 209.
5Parulkar A A, Pendergrass M L, Granda-Ayala R, et al. Nonhypoglyeemic Effects of Thiazolidinediones[J ]. Ann IntemMed, 2001, 134.. 61.
6Lansang M C, Coletti C, Ahmed S, et al. Effects of the PPAR- Agonist Rosiglitazone on Renal Haemodynamics and the Renin-Angiotensin System in Diabetes [J ]. Journal of Renin-Angiotensin-Aldosterone System, Sep, 2006, 7 : 175.
7Heidland A, Sebekova K, Sehinzel R. Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis, 2001, 38(4 Suppl 1) : S100.
8Gross P and Pistrosch F. PPAR agonists in diabetic nephropathy [ J ]. Nephrol Dial Transplant, 2007, 22 : 2095.
9Kanwar Y S, Wada J, Sun L, et al. Diabetic Nephropathy: Mechanisms of Renal Disease Progression[J]. Experimental Biology and Medicine, 2008, 233: 4.
10Huang Y, Border W A, Lawrence D A, et al. Mechanisms underlying the antifibrotic properties of noninhibitory PAI-1 (PAI-1R) in experimental nephritis[J]. Am J Physiol Renal Physiol, 2009, 297: F1045.
4Mur-veeman I,Hardy B, Steenbergen M, et al. Development of integrated care in England and the Netherlands: managing across public- privat eboundaries.Health Policy, 2003, 65(3) : 227-241.
